Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

NCT06304038 | Completed

• 1 other identifier: 2018
• Study Type: observational
• Target: 5,483
• Locations: 1 country
• Sites: 1

Brief Summary

Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.

Conditions

Influenza Vaccine; Cost-Benefit Analysis

Outcome Measures

Primary Outcomes (2)

• Effectiveness of the quadrivalent vaccine

  Effectiveness of the quadrivalent vaccine in reducing the number of working days lost due to influenza syndrome

  33 weeks

• Economic impact of the quadrivalent vaccine

  Economic impact (for the company and society) of vaccination as part of a vaccination campaign on the healthcare workers of the teaching hospital.

  33 weeks

Secondary Outcomes (2)

• Expected economic savings for each one percentage point increase in vaccination coverage

  33 weeks

• Non-economic incentives for healthcare personnel who decide to vaccinate

  33 weeks

Study Arms (2)

Vaccinated subjects

Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration

Drug: Flu Vaccine

Unvaccinated subjects

Healthcare workers that did not received flu vaccine

Interventions

Flu Vaccine DRUG

Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra

Vaccinated subjects

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population is represented by all employed healthcare workers of the FPG amounting to approximately 5000 (data provided by the Human Resources Department of the Hospital in December 2017). The case group consists of all healthcare workers vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital, filed on special registers. The control group consists of healthcare workers who were not vaccinated in the 2017-2018 season at the specially designated facilities within the Teaching Hospital.

You may qualify if:

• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

You may not qualify if:

• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Sponsors & Collaborators

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: lead

Study Sites (1)

Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Rome, 00168, Italy

Location

MeSH Terms

Conditions

Influenza, Human

Interventions

Influenza Vaccines

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 11, 2023
• First Posted: March 12, 2024
• Study Start: October 16, 2017
• Primary Completion: April 29, 2018
• Study Completion: November 14, 2019
• Last Updated: March 12, 2024

Record last verified: 2024-03

Locations

IT (1)